ALNYLAM PHARMACEUTICALS, INC. Shareholders' Equity
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Shareholders' Equity of $1.35 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.35B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.08B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $789.18M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $233.89M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.35B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $1.08B 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $789.18M 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $233.89M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $555.35M 10-Q · filed 2026-07-30 | $250.59M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $426.14M 10-Q · filed 2026-07-30 | $115.44M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $67.09M 10-Q · filed 2026-07-30 | |
| 2024-09-30 | $32.35M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | -$3.07M 10-Q · filed 2025-10-30 | |
| 2024-03-31 | -$219.27M 10-Q · filed 2025-10-30 | |
| 2023-12-31 | -$220.64M 10-K · filed 2026-02-12 | |
| 2023-09-30 | -$165.87M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | -$408.13M 10-Q · filed 2024-10-31 | |
| 2023-03-31 | -$259.24M 10-Q · filed 2024-10-31 | |
| 2022-12-31 | -$158.22M 10-K · filed 2026-02-12 | |
| 2022-09-30 | -$67.64M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $176.04M 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $401.17M 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $588.20M 10-K · filed 2025-02-13 | |
| 2021-09-30 | $755.89M 10-Q · filed 2022-10-27 | |
| 2021-06-30 | $853.36M 10-Q · filed 2022-10-27 | |
| 2021-03-31 | $926.19M 10-Q · filed 2022-10-27 | |
| 2020-12-31 | $1.02B 10-K · filed 2024-02-15 | |
| 2020-09-30 | $1.22B 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $1.40B 10-Q · filed 2021-10-28 | |
| 2020-03-31 | $1.35B 10-Q · filed 2021-10-28 | |
| 2019-12-31 | $1.44B 10-K · filed 2023-02-23 | |
| 2019-09-30 | $1.61B 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.76B 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $1.55B 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $1.30B 10-K · filed 2022-02-10 | |
| 2018-09-30 | $1.48B 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $1.62B 10-Q · filed 2019-10-31 | |
| 2018-03-31 | $1.75B 10-Q · filed 2019-10-31 | |
| 2017-12-31 | $1.77B 10-K · filed 2021-02-11 | |
| 2017-09-30 | $1.06B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $1.12B 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $830.90M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $920.22M 10-K · filed 2020-02-13 | |
| 2016-09-30 | $1.01B 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $1.10B 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $1.19B 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $1.26B 10-K · filed 2019-02-14 | |
| 2015-09-30 | $1.32B 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $1.41B 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $1.50B 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $936.27M 10-K · filed 2018-02-15 | |
| 2014-09-30 | $904.48M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $942.27M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $954.97M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $270.35M 10-K · filed 2017-02-15 | |
| 2013-09-30 | $297.58M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $308.18M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $311.56M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $134.05M 10-K · filed 2016-02-12 | |
| 2012-09-30 | $177.16M 10-Q · filed 2012-11-05 | |
| 2012-06-30 | $188.29M 10-Q · filed 2012-08-08 | |
| 2012-03-31 | $197.38M 10-Q · filed 2012-05-03 | |
| 2011-12-31 | $118.00M 10-K · filed 2015-02-13 | |
| 2011-09-30 | $127.87M 10-Q · filed 2011-11-03 | |
| 2011-06-30 | $136.55M 10-Q · filed 2011-08-03 | |
| 2011-03-31 | $145.57M 10-Q · filed 2011-05-05 | |
| 2010-12-31 | $158.23M 10-K · filed 2014-02-20 | |
| 2010-09-30 | $160.64M 10-Q · filed 2010-11-04 | |
| 2010-06-30 | $165.48M 10-Q · filed 2010-08-05 | |
| 2009-12-31 | $177.97M 10-K · filed 2013-02-19 | |
| 2008-12-31 | $202.13M 10-K · filed 2012-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |